| abstract |
The present disclosure provides novel crystalline forms of cabozantinib (S)-malate, designated as form-M 1 , M 2 , M 3 and M 4 and novel crystalline forms of cabozantinib free base, form-M 1 , M 2 and M 3 and methods of their production. The present disclosure also provides processes for the preparation of crystalline cabozantinib (S)-malate form N-1. |